Business
Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results
Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe Raised $100M+ in equity and debt financing to support commercial strategy and pipeline GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and comm
About this update from Senseonics Holdings, Inc.
[{"type":"image","alt":"Senseonics Holdings, Inc.","displaySize":"","headline":null,"caption":"Senseonics Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":259,"height":48,"url":"https://media.zenfs.com/en/globenewswire.com/352de1d24c4134f17c1d3a538ac3ac2c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/65Qp4GafRnzuTaIHxi_ZvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/352de1d24c4134f17c1d3a538ac3ac2c","width":259,"height":48},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/65Qp4GafRnzuTaIHxi_ZvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4/https://media.zenfs.com/en/globenewswire.com/352de1d24c4134f17c1d3a538ac3ac2c","width":259,"height":48}},"lazy":false},{"type":"text","content":"Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year","length":72,"tagName":"p"},{"type":"text","content":"Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) ","length":78,"tagName":"p"},{"type":"text","content":"Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe","length":90,"tagName":"p"},{"type":"text","content":"Raised $100M+ in equity and debt financing to support commercial strategy and pipeline ","length":86,"tagName":"p"},{"type":"text","content":"GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced first quarter 2026 financial results and provided a business update.","length":364,"tagName":"p"},{"type":"text","content":"Recent Highlights & Accomplishments","length":39,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued commercial momentum for Eversense 365 in the US, primarily driven by direct-to-consumer marketing efforts, with DTC new patient adds up nearly 100% year-over-year.","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"Achieved gross margin of 59% in Q1, an increase of 35% year-over-year, reflecting benefits from the commercial transition, scale and manufacturing effic...